Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service incontinence, prolapse & sacral neuromodulation cases in Georgia: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (219 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 24 | 2,442 | 43% |
| 2020 | 23 | 2,115 | 46% |
| 2021 | 26 | 2,556 | 51% |
| 2022 | 39 | 2,512 | 54% |
| 2023 | 40 | 2,689 | 57% |
| 2024 | 34 | 2,423 | 59% |
| 2025 from claims | – | 2,309 2,119–2,443 | 60% |
| 2026 forecast | – | 2,377 2,092–2,743 | 60% |
| 2027 forecast | – | 2,440 2,086–2,908 | 61% |
| 2028 forecast | – | 2,505 2,090–3,067 | 62% |
| 2029 forecast | – | 2,570 2,099–3,223 | 62% |
| 2030 forecast | – | 2,637 2,113–3,379 | 63% |
Slings, artificial sphincter, colpopexy, sacral neuromodulation, penile prosthesis. Professional codes (what the surgeon bills): CPT 57288, 53440, 53445, 57425, 57282, 57283, 64581, 64590, 54405.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 58% of the cases CMS names in Georgia; 19 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 86% hospital outpatient, 14% surgery center.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 107 | 6,731+0.7%/yr | +0.7%/yr | 3.0 | 30% | 7,480 in 2030+1.8%/yr |
| Texas | 85 | 6,023−0.4%/yr | −0.4%/yr | 2.8 | 24% | 8,340 in 2030+5.6%/yr |
| Tennessee | 43 | 2,360−3.4%/yr | −3.4%/yr | 3.3 | 26% | 2,650 in 2030+1.9%/yr |
| North Carolina | 32 | 2,349−2.5%/yr | −2.5%/yr | 2.4 | 5% | 2,230 in 2030−0.8%/yr |
| Virginia | 31 | 2,058−0.5%/yr | −0.5%/yr | 2.0 | 11% | 2,110 in 2030+0.4%/yr |
| South Carolina | 21 | 1,697−2.4%/yr | −2.4%/yr | 2.5 | 15% | 2,220 in 2030+4.6%/yr |
| Maryland | 35 | 1,684+0.8%/yr | +0.8%/yr | 1.9 | 34% | 1,910 in 2030+2.1%/yr |
| Oklahoma | 26 | 1,344−7%/yr | −7%/yr | 2.8 | 10% | 1,310 in 2030−0.5%/yr |
| Alabama | 17 | 1,302−0.1%/yr | −0.1%/yr | 2.9 | 16% | 1,480 in 2030+2.2%/yr |
| Arkansas | 21 | 1,234−4.1%/yr | −4.1%/yr | 3.2 | 30% | 1,060 in 2030−2.6%/yr |
| Kentucky | 10 | 902−8.4%/yr | −8.4%/yr | 2.0 | 11% | 950 in 2030+0.9%/yr |
| Mississippi | 14 | 901−6.8%/yr | −6.8%/yr | 2.4 | 45% | 1,040 in 2030+2.4%/yr |
| Louisiana | 10 | 866−4%/yr | −4%/yr | 2.1 | 3% | 710 in 2030−3.3%/yr |
| West Virginia | 6 | 311−5%/yr | −5%/yr | 1.5 | 0% | 360 in 2030+2.4%/yr |
| District of Columbia | 4 | 288+6.1%/yr | +6.1%/yr | 4.6 | 13% | 350 in 2030+3.4%/yr |
| Delaware | 3 | 284−1.8%/yr | −1.8%/yr | 1.6 | 0% | 370 in 2030+4.5%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| BPH procedures | 60 | 5,270−5.6%/yr | −5.6%/yr | 6.11.2× | 42% | 4,930 in 2030−1.1%/yr |
| Kidney stone management | 109 | 4,711−1.3%/yr | −1.3%/yr | 5.51.1× | 17% | 5,540 in 2030+2.7%/yr |
| Hysterectomy, hysteroscopy & ablation | 18 | 2,052−1%/yr | −1%/yr | 2.61.0× | 8% | 2,340 in 2030+2.2%/yr |
| Prostatectomy & nephrectomy | 20 | 1,026−0.3%/yr | −0.3%/yr | 1.31.1× | 0% | 1,080 in 2030+0.9%/yr |
Incontinence, prolapse & sacral neuromodulation in every state, and its device makers · Every procedure market in Georgia · Every state · Compare with Florida
Coloplast leads with 34% of company spending on these surgeons in 2025, −2 pts on 2024.
In 2025, 8 companies reported engagement with Georgia’s surgeons worth $334K in consulting, speaking, meals and travel tied to these products, about $9,825 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 46 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.